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Available onlineAbstract
A 16-year-old boy with cystic fibrosis developed ‘cepacia syndrome’ 9 years after the first isolation of Burkholderia multivorans. It is
important to recognise that ‘cepacia syndrome’ is not restricted to those infected with genomovar type III strains and that rapid, irreversible
clinical decline can occur many years after the 1st isolation of Burkholderia cepacia complex (Bcc).
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Burkholderia cepacia complex (Bcc) is an important
pathogen in cystic fibrosis. It is now recognised that within
Bcc, there are 10 closely related species or ‘genomovars’.
Infection with Bcc may result in an accelerated decline in
respiratory function and can reduce life expectancy [1].
Around 20% of infected patients develop ‘cepacia syn-
drome’ [1], characterized by a rapidly progressive pneumo-
nic illness, marked pyrexia, multi-organ failure, confluent
chest X-ray changes and positive blood cultures.
‘Cepacia syndrome’ was thought to occur soon after the
first isolation of Bcc [2] but has been reported 31 months
later [2].
Bcc genomovar III (gvIII) and Burkholderia multivorans
(gvII) are the most prevalent in CF. There are wide geo-
graphical variations in the prevalence of the genomovars. In
the USA, gvIII and II account for 50% and 37.8% of all Bcc
infections in the CF population. The corresponding figures
for Canada are 80% and 9.3%, and for Italy, 72.6% and
4.8% [3]. Little is known about the actual prevalence of gvII
in the UK, but it may be higher. At our centre, 16 patients
have isolated Bcc in the last 15 months. Fifty-six percent of
these isolates were identified as gvII organisms.1569-1993/$ - see front matter D 2004 European Cystic Fibrosis Society. Publish
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patient spread of gvII strains has also been reported [3].
‘Cepacia syndrome’ is usually associated with gvIII strains.
There has only been one report of ‘cepacia syndrome’ being
related to a gvII strain [4].2. Case report
A 16-year-old boy with cystic fibrosis was admitted
with a respiratory exacerbation 8 weeks after his last
intravenous antibiotic treatment. He had been diagnosed
with cystic fibrosis at 3 months of age (homozygous delta F
508). At 5 years of age, he became chronically infected
with Pseudomonas aeruginosa (Pa) and required frequent
courses of intravenous antibiotics. For the last few years, he
had been treated with IV antibiotics every 3 months. At 7
years of age, he became chronically colonized with Bcc
although his clinical status remained stable for the next 9
years with an FEV1 ranging between 50% and 70% of the
predicted.
On admission, he had been unwell for 5 days with
shortness of breath and an increased cough, productive of
brown sputum. He was pyrexial at 38 jC and was slightly
dyspnoeic. His FEV1 was 46% of the predicted. Sputum
samples grew Pa and Bcc. He was treated with intravenous
tobramycin and piperacillin–tazobactam, and physiotherapy
increased to three times a day. At day 7, he was showinged by Elsevier B.V. All rights reserved.
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cough lessened.
He deteriorated on day 11, with marked pyrexia to 39.5j,
rigors, nausea and vomiting. The peripheral blood white cell
count showed a neutrophilia (16 10*9/l). C-reactive pro-
tein was raised at 190mg/l. Teicoplanin and fluconazole
were empirically added to his antimicrobial therapy. Fluco-
nazole was later changed to amphotericin. Because of
persisting pyrexia, his indwelling vascular access device
was removed on day 14 but without improvement in his
clinical state. Blood culture samples were not obtained from
the vascular access device, but there was no growth from
peripheral blood cultures samples. He required 35% face
mask oxygen and developed renal and hepatic impairment
necessitating admission to intensive care and haemofiltra-
tion. Tobramycin levels were monitored and doses adjusted
accordingly. Levels were not significantly elevated. Liver
function was deranged with an alanine aminotransferase
level of 77U/1 and an alkaline phosphatase level of 1062U/
1. He developed a coagulopathy with a raised prothrombin
time (26 s) and activated partial thromboplastin time (100 s),
reduced fibrinogen ( < 0.5g/l) and markedly elevated fibrin-
degradation products ( > 8000mg/l). The clinical picture was
thought to be consistent with sepsis. On day 18, a venous
line was placed under general anaesthetic and it was not
possible to extubate him. An episode of haematemesis on
day 18 was investigated with upper GI endoscopy, and there
was no evidence of varices. He was hypotensive at 75/40
mm Hg, and despite treatment with noradrenaline and
dobutamine, he had a cardiac arrest on day 19, requiring
full cardiopulmonary resuscitation for 5 min. Over the
subsequent 4 days, his ventilatory requirements increased
with bilateral patchy infiltrates in the middle and lower
zones on chest X-ray. On day 25, despite ventilation,
inotropic support and haemofiltration, he remained acidotic
and hypotensive. Further intensification of treatment was
felt to be inappropriate, treatment was withdrawn and the
patient died. An autopsy was not performed.
Subsequently, Bcc was isolated from four antemortem
blood culture samples. Molecular methods confirmed that the
blood culture isolate was B. multivorans (gvII). In vitro, the
organism was sensitive to piperacillin–tazobactam, merope-
nem, imipenem and ceftazidime. It was resistant to tobramy-
cin, ciprofloxacin, gentamicin, amikacin, colistin and
aztreonam. Pa was isolated from one blood culture sample,
taken from his vascath. This organism was sensitive to
tobramycin and gentamicin and resistant to piperacillin–tazobactam, ciprofloxacin, imipenem and ceftazidime. Viral
studies performed on sputum and bronchial lavage specimens
were negative. Viral serology showed no significant titres.3. Discussion
GvII strains are prevalent in patients with CF, but the
association of ‘cepacia syndrome’ with a gvII strain is
highly unusual and is of important clinical significance.
This boy developed ‘cepacia syndrome’ 9 years after first
becoming colonized with Bcc. It is hypothesized that on his
final presentation, he may have had a viral illness that
reduced his host immunity, possibly increasing his suscep-
tibility to develop ‘cepacia syndrome’.
In summary, this case highlights that ‘cepacia syndrome’
is not limited to organisms within genomovar III infection
and can occur many years after Bcc is first isolated. It is
important that clinicians are aware of this.
In this case, ‘cepacia syndrome’ occurred while the
patient was being treated with an antibiotic to which the
organism was sensitive in vitro, highlighting that sensitivity
to antibiotics in vitro does not always correspond to clinical
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